Authors: Janik, JE Miller, LL Korn, EL Stevens, D Curti, BD Smith, JW Sznol, M Conlon, KC Sharfman, W Urba, WJ Gause, BL Longo, DL

Citation: Je. Janik et al., A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma, BLOOD, 97(7), 2001, pp. 1942-1946

Authors: Longo, DL Duffey, PL Gribben, JG Jaffe, ES Curti, BD Gause, BL Janik, JE Braman, VM Esseltine, D Wilson, WH Kaufman, D Wittes, RE Nadler, LM Urba, WJ

Citation: Dl. Longo et al., Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: Results of a phase II study, CANCER J, 6(3), 2000, pp. 146-150

Authors: Arun, B Curti, BD Longo, DL Stevens, D Alvord, WG Gause, BL Watson, T Kopp, WC Janik, JE

Citation: B. Arun et al., Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia, CA J SCI AM, 6(1), 2000, pp. 21-24

Authors: Janik, JE Miller, LL Kopp, WC Taub, DD Dawson, H Stevens, D Kostboth, P Curti, BD Conlon, KC Dunn, BK Donegan, SE Ullrich, R Alvord, WG Gause, BL Longo, DL

Citation: Je. Janik et al., Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients, CLIN IMMUNO, 93(3), 1999, pp. 209-221

Authors: Bendandi, M Gocke, CD Kobrin, CB Benko, FA Sternas, LA Pennington, R Watson, TM Reynolds, CW Gause, BL Duffey, PL Jaffe, ES Creekmore, SP Longo, DL Kwak, LW

Citation: M. Bendandi et al., Complete molecular remissions induced by patient-specific vaccination plusgranulocyte-monocyte colony-stimulating factor against lymphoma, NAT MED, 5(10), 1999, pp. 1171-1177

Authors: Miller, LL Korn, EL Stevens, DS Janik, JE Gause, BL Kopp, WC Holmlund, JT Curti, BD Sznol, M Smith, JW Urba, WJ Donegan, SE Watson, TM Longo, DL

Citation: Ll. Miller et al., Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin, BLOOD, 93(10), 1999, pp. 3250-3258